161 related articles for article (PubMed ID: 23400406)
1. 2D- and 3D-QSAR studies of a series of benzopyranes and benzopyrano[3,4b][1,4]-oxazines as inhibitors of the multidrug transporter P-glycoprotein.
Jabeen I; Wetwitayaklung P; Chiba P; Pastor M; Ecker GF
J Comput Aided Mol Des; 2013 Feb; 27(2):161-71. PubMed ID: 23400406
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, biological evaluation and 3D-QSAR studies of new chalcone derivatives as inhibitors of human P-glycoprotein.
Parveen Z; Brunhofer G; Jabeen I; Erker T; Chiba P; Ecker GF
Bioorg Med Chem; 2014 Apr; 22(7):2311-9. PubMed ID: 24613626
[TBL] [Abstract][Full Text] [Related]
3. Probing the stereoselectivity of P-glycoprotein-synthesis, biological activity and ligand docking studies of a set of enantiopure benzopyrano[3,4-b][1,4]oxazines.
Jabeen I; Wetwitayaklung P; Klepsch F; Parveen Z; Chiba P; Ecker GF
Chem Commun (Camb); 2011 Mar; 47(9):2586-8. PubMed ID: 21173990
[TBL] [Abstract][Full Text] [Related]
4. Grid-independent Descriptors (GRIND) Analysis and SAR Guided Molecular Docking Studies to Probe Selectivity Profiles of Inhibitors of Multidrug Resistance Transporters ABCB1 and ABCG2.
Shafi T; Jabeen I
Curr Cancer Drug Targets; 2017; 17(2):177-190. PubMed ID: 27585695
[TBL] [Abstract][Full Text] [Related]
5. Combined QSAR and molecule docking studies on predicting P-glycoprotein inhibitors.
Tan W; Mei H; Chao L; Liu T; Pan X; Shu M; Yang L
J Comput Aided Mol Des; 2013 Dec; 27(12):1067-73. PubMed ID: 24322389
[TBL] [Abstract][Full Text] [Related]
6. Lead identification for modulators of multidrug resistance based on in silico screening with a pharmacophoric feature model.
Langer T; Eder M; Hoffmann RD; Chiba P; Ecker GF
Arch Pharm (Weinheim); 2004 Jun; 337(6):317-27. PubMed ID: 15188221
[TBL] [Abstract][Full Text] [Related]
7. Pharmacophore modeling of nilotinib as an inhibitor of ATP-binding cassette drug transporters and BCR-ABL kinase using a three-dimensional quantitative structure-activity relationship approach.
Shukla S; Kouanda A; Silverton L; Talele TT; Ambudkar SV
Mol Pharm; 2014 Jul; 11(7):2313-22. PubMed ID: 24865254
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of P-glycoprotein by natural products in human breast cancer cells.
Chung SY; Sung MK; Kim NH; Jang JO; Go EJ; Lee HJ
Arch Pharm Res; 2005 Jul; 28(7):823-8. PubMed ID: 16114498
[TBL] [Abstract][Full Text] [Related]
9. Intramolecular distribution of hydrophobicity influences pharmacological activity of propafenone-type MDR modulators.
Pleban K; Hoffer C; Kopp S; Peer M; Chiba P; Ecker GF
Arch Pharm (Weinheim); 2004 Jun; 337(6):328-34. PubMed ID: 15188222
[TBL] [Abstract][Full Text] [Related]
10. QSAR and 3D-QSAR of phenothiazine type multidrug resistance modulators in P388/ADR cells.
Tsakovska IM
Bioorg Med Chem; 2003 Jul; 11(13):2889-99. PubMed ID: 12788359
[TBL] [Abstract][Full Text] [Related]
11. Control of P-glycoprotein activity by membrane cholesterol amounts and their relation to multidrug resistance in human CEM leukemia cells.
Gayet L; Dayan G; Barakat S; Labialle S; Michaud M; Cogne S; Mazane A; Coleman AW; Rigal D; Baggetto LG
Biochemistry; 2005 Mar; 44(11):4499-509. PubMed ID: 15766280
[TBL] [Abstract][Full Text] [Related]
12. Structure-activity relationships of new inhibitors of breast cancer resistance protein (ABCG2).
Pick A; Müller H; Wiese M
Bioorg Med Chem; 2008 Sep; 16(17):8224-36. PubMed ID: 18678495
[TBL] [Abstract][Full Text] [Related]
13. Molecular factors influencing the affinity of flavonoid compounds on P-glycoprotein efflux transporter.
Vázquez RN; Camargo AB; Marchevsky EJ; Luco JM
Curr Comput Aided Drug Des; 2014; 10(3):250-8. PubMed ID: 25756670
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity relationship: analyses of p-glycoprotein substrates and inhibitors.
Wang RB; Kuo CL; Lien LL; Lien EJ
J Clin Pharm Ther; 2003 Jun; 28(3):203-28. PubMed ID: 12795780
[TBL] [Abstract][Full Text] [Related]
15. A new anthracycline with potent anti-leukemic activity overcomes P-glycoprotein multidrug resistance.
Andrivon W; Monneret C; Nafziger J; Florent JC; Guillosson JJ
Leuk Res; 1998 Aug; 22(8):719-25. PubMed ID: 9680099
[TBL] [Abstract][Full Text] [Related]
16. Drug-protein hydrogen bonds govern the inhibition of the ATP hydrolysis of the multidrug transporter P-glycoprotein.
Chufan EE; Kapoor K; Ambudkar SV
Biochem Pharmacol; 2016 Feb; 101():40-53. PubMed ID: 26686578
[TBL] [Abstract][Full Text] [Related]
17. Modulation of P-glycoprotein activity by novel synthetic curcumin derivatives in sensitive and multidrug-resistant T-cell acute lymphoblastic leukemia cell lines.
Ooko E; Alsalim T; Saeed B; Saeed MEM; Kadioglu O; Abbo HS; Titinchi SJJ; Efferth T
Toxicol Appl Pharmacol; 2016 Aug; 305():216-233. PubMed ID: 27318188
[TBL] [Abstract][Full Text] [Related]
18. Structure-activity relationship of natural and synthetic coumarins inhibiting the multidrug transporter P-glycoprotein.
Raad I; Terreux R; Richomme P; Matera EL; Dumontet C; Raynaud J; Guilet D
Bioorg Med Chem; 2006 Oct; 14(20):6979-87. PubMed ID: 16824763
[TBL] [Abstract][Full Text] [Related]
19. Ligand and structure-based classification models for prediction of P-glycoprotein inhibitors.
Klepsch F; Vasanthanathan P; Ecker GF
J Chem Inf Model; 2014 Jan; 54(1):218-29. PubMed ID: 24050383
[TBL] [Abstract][Full Text] [Related]
20. Modeling drug-drug interactions of AZD1208 with Vincristine and Daunorubicin on ligand-extrusion binding TMD-domains of multidrug resistance P-glycoprotein (ABCB1).
Marques MB; de Oliveira PV; Fagan SB; Oliveira BR; da Silva Nornberg BF; Almeida DV; Marins LF; González-Durruthy M
Toxicology; 2019 Jan; 411():81-92. PubMed ID: 30339824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
